With its main patent for Fosamax set to expire in February, Merck & Co. has reportedly struck an authorized generic deal with an anonymous company to market a generic copy of its popular osteoporosis drug, which could be on store shelves as early as next month.
Illumina Inc. will pay Affymetrix Inc. $90 million without admitting liability under a settlement agreement that should resolve litigation between the genetic analysis companies in the United States, England and Germany.
A judge ruled that a consolidated class action lawsuit filed against Enzo Biochem Inc., alleging the company and certain officers conspired to inflate the price of the stock through misrepresentations and omissions about the efficacy of its HIV treatments, should proceed to trial.
An appeals court has paved the way for the city of San Francisco to extend health coverage to its uninsured residents by staying a district court's earlier ruling that the city's landmark employer-funded health care program is preempted by federal law.
A proposed class action lawsuit that accused Pfizer Inc. of deceptively marketing its blockbuster cholesterol treatment Lipitor has been dismissed after more than two years of litigation in which the plaintiffs' claims were slowly winnowed down.
Plaintiffs in the Celebrex product liability case have suffered a setback in their quest against Pfizer Inc., with the drug maker touting a judge's recent decision to exclude certain expert evidence as a sign that many of the suits over the anti-inflammatory drug will soon be dismissed.
The court order enjoining Boston Scientific Corp. from firing subsidiary Advanced Bionics Corp.'s co-CEOs should be vacated, the medical device companies have agreed, abandoning an earlier merger agreement.
Solvay Pharmaceuticals Inc. has been hit with a purported wage-and-hour collective action claiming the pharmaceutical company failed to pay hundreds of sales representatives overtime pay in violation of the Fair Labor Standards Act.
A district judge in California has granted summary judgment to Roche Laboratories Inc. in a proposed wage-and-hour class action against the company.
New Jersey trial lawyers, consumer groups and insurers are among those closely watching as the governor prepares to weigh in on a contentious bill that would open the door to wrongful death lawsuits, after the measure squeezed through the state legislature this week.
The U.S. Food and Drug Administration took action against seven pharmacy operations on Wednesday, warning them that medical evidence does not support claims they make about their bioidentical hormone replacement drugs.
Warning letters recently sent by the Food and Drug Administration to pharmacies, alleging they made misleading claims about their bioidentical hormone replacement therapies, have set off a debate concerning where the FDA's authority ends and whether compounding pharmacies should be more closely regulated.
Medtronic Inc. has succeeded in transferring its trade secrets lawsuit against two former employees and the rival pharmaceuticals company they now work for from federal court, where the defendants had removed it, back to state court.
A Luxemburg-based investment firm has been appointed lead plaintiff in a consolidated shareholder class action against anti-cancer drug maker GPC Biotech AG despite concerns over a foreign investor's rights in U.S. securities suits.
A former Mayer Brown LLP patent litigator has joined Kenyon & Kenyon LLP in its New York City office as a partner who will help run the Life Sciences practice, Kenyon announced Thursday.
Teva Pharmaceutical Industries Ltd. has dropped a patent infringement lawsuit against Taro Pharmaceuticals Industries Ltd. over the congestive heart drug failure treatment carvedilol.
Shareholders of the former Schering AG have won their lawsuit seeking to force their new parent, Bayer AG, to turn over information on its 2006 acquisition of Schering.
A New York federal judge has found that Purdue Pharma LP did not engage in conduct that invalidated its patents for OxyContin in a ruling that the drug company claims severely damages antitrust claims against it in consolidated litigation.
Amid rising concern over the ethics of direct-to-consumer advertising, a recent study by a group of university researchers has found that most prescription drug ads on television do not present a fair balance of information, especially when it comes to the risk of side effects.
Crowell & Moring's health care and antitrust groups will soon benefit from the real-world experience of a former in-house counsel of a major medical device company, now that Karen A. Gibbs has joined the firm as a partner.